OGT Presents Promising Prostate Cancer Biomarker Panel Results at AACR

Oxford Gene Technology (OGT) has presented potentially highly significant, preliminary data on the development of a panel of biomarkers for the diagnosis of prostate cancer.

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has presented potentially highly significant, preliminary data on the development of a panel of biomarkers for the diagnosis of prostate cancer. In the pilot study, a set of biomarkers was identified which can distinguish prostate cancer from control samples with both sensitivity and specificity above 90%, far higher than existing diagnostic tests. These data were presented at the Fourth American Association for Cancer Research International Conference: Molecular Diagnostics in Cancer Therapeutic Development, in Denver on 27–30 September.

Prostate cancer caused an estimated 258,000 deaths worldwide in 2008, and is the second most common cause of cancer deaths in males in the US with approximately 32,000 deaths estimated for 2010. Currently, the most effective screening tests available are based on a single biomarker, prostate specific antigen (PS